Future clinical trials of targeted therapies for pemphigus
|
|
- Sophie Harrington
- 5 years ago
- Views:
Transcription
1 Future clinical trials of targeted therapies for pemphigus Aimee S. Payne, MD, PhD University of Pennsylvania September 17, 2017 Conflicts of interest: Founder of Tycho Therapeu9cs, focused on targeted therapies for pemphigus; inventor on a patent licensed to Novar9s for immunotherapy of autoimmune diseases including P/P
2 Precision medicine for pemphigus therapy Cancer therapy X Pemphigus therapy Prednisone Mycophenolate Azathioprine Methotrexate X
3 Strategies for targeted therapy in pemphigus Pep;de immunotherapy for tolerance induc;on in pemphigus vulgaris Targeted B cell deple;on in pemphigus vulgaris (CAAR- T)
4 Why all the a7en8on on pemphigus vulgaris? Pemphigus is considered one of the best, if not the best, defined autoimmune diseases in humans The desmoglein ELISA is % sensi;ve and specific for the diagnosis of pemphigus, which means that almost everyone with a pemphigus has a posi;ve test, and almost no one with a posi;ve test doesn t have pemphigus Pemphigus vulgaris represents 85% of all pemphigus cases, whereas pemphigus foliaceus is only 15% Pemphigoid is a bit more complicated because the an;body alone isn t necessarily enough to cause disease, you also need inflamma;on or other signals to develop blisters
5 Tolerance induc8on using pep8de- coupled cells htp:// Collect cells from a mouse with experimental mul;ple sclerosis Coat the cells with small parts of the protein targeted in disease Inject the coated cells back into the mouse disease resolves
6 Tolerance induc8on using pep8de coupled cells htp:// htps:// Collect cells from a human with mul;ple sclerosis Coat the cells with small parts of the protein targeted in disease Inject the coated cells back into the pa;ent Safety No adverse events related to therapy (1 pa;ent with metallic taste) 4 flares of disease in 10 pa;ents: Two within 1 month of treatment in pa;ents with severe disease Two 4 months aaer treatment Efficacy 4 of 10 pa;ents showed reduced protein- specific T cell responses
7 Tolerance induc8on using pep8de coupled cells: how does it work? htps:// pep;de- cells cause T cell anergy pep;de- cells cause dendri;c cells to tolerize Stand down! Induc;on of regulatory T cells T cells send signal: Make an;bodies! B cells respond
8 Tolerance induc8on using pep8de coupled cells: how does it work? htps:// pep;de- cells cause T cell anergy pep;de- cells cause dendri;c cells to tolerize Stand down! Induc;on of regulatory T cells T cells send signal: Make an;bodies! B cells respond
9 Cures of B cell leukemia with CAR- T cells Phase I/IIa trial 30 pa;ents: 90% complete remission 73% relapse- free Major toxici;es observed: Permanent B cell deple;on cytokine release syndrome Maude et al, NEJM 2014, 371:1507 ELIANA trial (NCT ): 82% CR in refractory leukemia Grupp et al, ASH #221, 2016 Ac?vate T cells Engineer them to express CARs Make millions more Nat. Rev. Clin. Oncol. 2013
10
11 Targeted B cell deple8on with CAAR- T cells htp://science.sciencemag.org/content/early/2016/06/29/science.aaf6756 B cells: all have CD19 on their surface, only a few have an an;- desmoglein an;body
12 Targeted B cell deple8on with CAAR- T cells htp://science.sciencemag.org/content/early/2016/06/29/science.aaf6756 An;- CD19 B cells: all have CD19 on their surface, only a few have an an;- desmoglein an;body
13 Targeted B cell deple8on with CAAR- T cells htp://science.sciencemag.org/content/early/2016/06/29/science.aaf6756 An;- CD19 Desmoglein B cells: all have CD19 on their surface, only a few have an an;- desmoglein an;body
14 CAAR T cells cure pemphigus in mouse models htp://science.sciencemag.org/content/early/2016/06/29/science.aaf6756 Dsg3 CAAR control Day 5 Day 12
15 Poten8al advantages of CAAR T cells htp://science.sciencemag.org/content/early/2016/06/29/science.aaf6756 CAAR T cells: Specifically kill an;- Dsg3 B cells while sparing other B cells, without detectable off- target toxicity Offer the poten;al for long- term cure of disease May not be suscep;ble to side effects seen with CAR- T therapy of cancer given that pemphigus B cells are rare Could theore;cally be applied to any an;body- mediated disease Next steps: meet the FDA requirements to launch a clinical trial of CAAR- Ts in pemphigus
16 How soon to clinical trials? (1-3 years) Pep;de immunotherapy for tolerance induc;on in pemphigus vulgaris Targeted B cell deple;on in pemphigus vulgaris (CAAR- T)
17 An9gen- specific therapies for pemphigus vulgaris Innova;ve therapeu;c strategies are on the horizon for pemphigus If proven successful in pemphigus vulgaris, therapies for other forms of P/P, as well as other autoimmune diseases, may follow There will be challenges in designing trials for rare diseases when the cost of therapy is currently high Clinical trials are ul;mately the only way to know whether therapy is safe and effec;ve in humans
18 Acknowledgments Penn Dermatology Christoph Ellebrecht Jinmin Lee Eun- Jung Choi Michael Cho Xuming Mao John Seykora Arben Nace George Cotsarelis Mike Milone, MD/PhD Christoph Ellebrecht, MD Jinmin Lee, PhD Penn Pathology Michael Milone Vijay Bhoj Selene Nunez- Cruz Masayuki Amagai (Keio University) Jun amagami Antonio Lanzavecchia (ETH Zurich) Giovanni Di Zenzo
19 Targe8ng inflamma8on in bullous pemphigoid Autoan;bodies bind skin Ac;va;on of complement Release of chemicals to bring in immune cells (IL- 17, X eotaxin, X others) ixekizumab ber;limumab Inflammatory cells release damaging enzymes or chemicals Skin blistering htp://link.springer.com/ar;cle/ %2fs y
20 Benefits and risks in ongoing pemphigoid trials RITUXIMAB Ixekizumab Already FDA- approved for psoriasis No clinical data on efficacy in BP, but epidemiologic studies have shown that psoriasis is more common in BP pa;ents (5x more common in those and 43x more common in those under 60 years of age), sugges;ng poten;al common causes Risks = injec;on site reac;ons, upper respiratory or fungal infec;ons Ber;limumab Preliminary data in a few BP pa;ents shows an 84% improvement in disease ac;vity Side effect profile unclear, but eosinophil blockade is generally well tolerated, mainly a risk of upper respiratory infec;ons
A case of bullous pemphigoid following pemphigus foliaceus
#2228 A case of bullous pemphigoid following pemphigus foliaceus Priyanka Vedak MD 1, Danielle Levine MD 1,3, Lyn Duncan MD 2,3, Hensin Tsao 1,3, Daniela Kroshinsky MD MPH 1,3 1. Department of Dermatology,
More informationHypersensi)vity Reac)ons. Kris)ne Kra2s, M.D.
Hypersensi)vity Reac)ons Kris)ne Kra2s, M.D. Hypersensi)vity Reac)ons Outline Introduc)on Introduc)on Normal immune reac)ons do their job without hur)ng the host. Some)mes, immune reac)ons can be excessive,
More informationPhysiology Unit 3 THE SPECIFIC IMMUNE RESPONSE
Physiology Unit 3 THE SPECIFIC IMMUNE RESPONSE The Adap4ve Arm of the Immune System Specific Immune Response Internal defense against a specific pathogen Acquired as you are exposed to diseases The immune
More informationImmunology. Overview. Kris.ne Kra1s, M.D.
Immunology Overview Kris.ne Kra1s, M.D. Immunology Overview Defini.ons Cells Lymphocytes An.gen-presen.ng cells Effector cells Responses The innate immune response Capturing and displaying an.gens Cell-mediated
More informationJPEMS 2014 Basic Immunology module Activation and functions of T lymphocytes
JPEMS 2014 Basic Immunology module Activation and functions of T lymphocytes Teacher: Pr. Régis Josien, Laboratoire d Immunologie, CHU Nantes Regis.Josien@univ-nantes.fr 1 An#gen recogni#on by T cells
More informationClinical spectrum and therapeutic approach in pemphigus vulgaris
Clinical spectrum and therapeutic approach in pemphigus vulgaris Michael Hertl Department of Dermatology and Allergology Philipps University, Marburg, Germany F125: Bullous Diseases: Diagnostic and Management
More informationAutoimmune Diseases with Oral Manifestations
Autoimmune Diseases with Oral Manifestations Martin S. Greenberg DDS, FDS RCSEd Professor Emeritus Department of Oral Medicine University of Pennsylvania Disclosure Statement I have no actual or potential
More informationAbstract #163 Michael Kalos, PhD
LONG TERM FUNCTIONAL PERSISTENCE, B CELL APLASIA AND ANTI LEUKEMIA EFFICACY IN REFRACTORY B CELL MALIGNANCIES FOLLOWING T CELL IMMUNOTHERAPY USING CAR REDIRECTED REDIRECTED T CELLS TARGETING CD19 Abstract
More informationDesigning An)gen- specific Immunotherapy for Treatment of Type 1 Diabetes.
Designing An)gen- specific Immunotherapy for Treatment of Type 1 Diabetes. Kristin V. Tarbell Immune Tolerance Unit, Diabetes Endocrinology and Obesity Branch, NIDDK Outline Background on type 1 diabetes
More informationCanine Atopic Derma//s and the IL-31 Inhibitors
Canine Atopic Derma//s and the IL-31 Inhibitors Daniel O. Morris, DVM, MPH, DACVD Professor of Dermatology & Allergy School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA DISCLOSURE
More informationRheumatoid Arthri4s (RA)
Rheumatoid Arthri4s (RA) Chronic, systemic autoimmune disease Inflamma4on of connec4ve 4ssue in diarthrodial (synovial) joints Periods of remission and exacerba4on Extraar4cular manifesta4ons Extraar4cular
More informationDangerous Dermatoses: TEN, SJS, EM, BP, PV Pearls
Dangerous Dermatoses: TEN, SJS, EM, BP, PV Pearls Jacob Levitt, MD, FAAD Professor, Vice Chair, Program Director The Mount Sinai Medical Center, New York, NY Disclosures I have served on Advisory Boards
More informationAnnual Scientific Meeting 2018
Annual Scientific Meeting 2018 Reported by HYY Kwong, HL Lo, SH Ng, PY Ngan, W Ngan, HW Wong, WF Wu Date: 23-24 June 2018 Venue: Sheraton Hong Kong Hotel & Towers, Tsim Sha Tsui, Hong Kong Organiser: Hong
More informationIntroduc)on to Immunology. T Cell Development
Introduc)on to Immunology T Cell Development Adolfo Ferrando af2196@columbia.edu Thymic stroma cells provide the microenvironment for T cell development. T cells develop from progenitors that are derived
More informationTreatment with steroids and immunosuppressants
Treatment with steroids and immunosuppressants Donna Culton, MD, PhD University of North Carolina IPPF 2017 Annual Patient Conference Newport Beach, CA September 16, 2017 Factors that will influence therapy
More informationCurrent concepts of autoimmune bullous diseases Advances in pathogenesis. Luca Borradori
Current concepts of autoimmune bullous diseases Advances in pathogenesis Luca Borradori Dept. of Dermatology Inselspital, University Hospital of Berne Switzerland Luca.Borradori@insel.ch Autoimmune bullous
More informationClinical Trials and You. Annette Czernik, MD, FAAD Icahn School of Medicine at Mount Sinai
Clinical Trials and You Annette Czernik, MD, FAAD Icahn School of Medicine at Mount Sinai King Nebuchadnezzar ruled Babylon until 562 BCE (according to The Bible) Purpose and history of clinical trials
More informationCARs vs. BiTE in ALL. David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center
CARs vs. BiTE in ALL David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center Disclosure Information David L Porter Speaker and members of study
More informationChapter 22. Immunity
Chapter 22 Immunity Body Defenses-Immunity The Lympha6c System and Body Defenses Body defenses provide resistance to fight infec6on, illness, and disease Two categories of defenses 1. Innate (nonspecific)
More informationIMMUNE RESPONSE TO INFECTIOUS DISEASES
IMMUNE RESPONSE TO INFECTIOUS DISEASES Immune Response to Bacterial Infection Characteris*cs of Bacteria 1 X 2 X 3 X 4 X 5 X 6 X 7 X Bacterial Diseases Any part of the body can be infected by many Infec;ous
More informationForward Looking Statements
March 12, 2015 1 Forward Looking Statements This presenta5on contains forward- looking statements within the meaning of the Private Securi5es Li5ga5on Reform Act of 1995 that involve substan5al risks and
More informationInves&gación básica y curación del VIH-1
Inves&gación básica y curación del VIH-1 Javier Mar&nez-Picado 24 th Conference on Retroviruses and Opportunis6c Infec6ons UNIVERSITAT DE VIC Empezamos bien cart: How Early is Early Enough? Sáez-Cirion
More informationRESEARCH HIGHLIGHTS NEW IPPF OUTREACH MANAGER ADVOCATING ON CAPITOL HILL
Quarterly RESEARCH HIGHLIGHTS NEW IPPF OUTREACH MANAGER ADVOCATING ON CAPITOL HILL Journal of the International Pemphigus & Pemphigoid Foundation Goes to Austin: Patient Conference Recap DR. AIMEE PAYNE'S
More informationComparing Arsenic Trioxide with Realgar-Indigo naturalis formula in children with Acute Promyelocy=c Leukemia:
Comparing Arsenic Trioxide with Realgar-Indigo naturalis formula in children with Acute Promyelocy=c Leukemia: An Interim Report of Mul=center and Randomized clinical Trial (SCCLG-APL) The Southern China
More informationCAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes. Shannon L.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes Shannon L. Maude, MD, PhD CTL019 cell Lentiviral vector Anti-CD19 CAR construct CD19 Native
More informationCorporate Presentation. December 2018
Corporate Presentation December 2018 OTCQB: IMNP www.immunepharma.com Forward-Looking Statements This presentation and oral statements made by representatives of the Company may contain projections or
More informationA New Innova+ve Approach to Integrate Pa+ent Preferences into the Sta+s+cal Design for Clinical Trials: A Collabora+ve Case Study
A New Innova+ve Approach to Integrate Pa+ent Preferences into the Sta+s+cal Design for Clinical Trials: A Collabora+ve Case Study A Collabora)on of the Medical Device Innova)on Consor)um, FDA, MIT, RTI
More informationBetalu'n ( 177 Lu-HH1)
Betalu'n ( 177 Lu-HH1) Arne Kolstad Oslo University Hospital Norway May 15, 2017 Disclosures of: Arne Kolstad Company name Research support Employee Consultant Stockholder Speakers bureau Nordic Nanovector
More informationOral mucositis associated with targeted therapy and immunotherapy: what s old is new again
Oral mucositis associated with targeted therapy and immunotherapy: what s old is new again Nathaniel Treister, DMD, DMSc Associate Surgeon Brigham and Women s Hospital Associate Professor Harvard School
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More information10/25/2018. Autoimmunity and how to treat it. Disclosure. Why do we get autoimmunity? James Verbsky MD/PhD Pediatric Rheumatology/Immunology
Autoimmunity and how to treat it James Verbsky MD/PhD Pediatric Rheumatology/Immunology Disclosure None I will mention drug names and some brand names but I have no financial interest or any other ties
More informationPrecision CAR T Cell Therapeutics. Carl June October 15, 2018
Precision CAR T Cell Therapeutics Carl June October 15, 2018 Disclosure Information Carl June I have the following financial relationships to disclose: Consultant for: Novartis, Immune Design, Viracta,
More informationPharmacological treatments. Jann Arends Tumor Biology Center Freiburg, Germany
Pharmacological treatments Jann Arends Tumor Biology Center Freiburg, Germany Pharmacologic treatment: Basic concept Interfere with undesired physiology Drug a specific target Major problems in cachexia
More informationCorporate Presentation. August 2018
Corporate Presentation August 2018 OTCQB: IMNP www.immunepharma.com Forward-Looking Statements This presentation and oral statements made by representatives of the Company may contain projections or other
More informationWHO posi)on paper on hepa))s A vaccines
WHO posi)on paper on hepa))s A vaccines Geneva, Switzerland Published in the Weekly Epidemiological Record on 13 July 2012 Transmission and incidence Hepa))s A virus (HAV) is transmiled primarily via the
More informationIn developed countries (like the U.S.) we really only have to worry about viruses and bacteria
The immune system dis1nguishes self from non- self When we think of the immune system, we o>en only think that it protects us from pathogens (bacteria, viruses, fungi, parasites) But, the immune system
More informationWhat's New in Oncodermatopathology: Immunotherapy Reactions
What's New in Oncodermatopathology: Immunotherapy Reactions Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania March
More informationDepartment of Dermatology, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo , Japan 2
Dermatology Research and Practice Volume 2010, Article ID 931340, 5 pages doi:10.1155/2010/931340 Case Report Paraneoplastic Pemphigus Presenting as Mild Cutaneous Features of Pemphigus Foliaceus and Lichenoid
More informationBIOLOGICS: A NEW HOPE. Alastair Denniston, University Hospitals Birmingham NHSFT & University of Birmingham
BIOLOGICS: A NEW HOPE Alastair Denniston, University Hospitals Birmingham NHSFT & University of Birmingham And beyond... Biologics in Uvei
More informationTransla&onal Opportuni&es
Suppor&ng the UK s Transla&onal Research in Paediatric Rheumatology Experience of the UK s Paediatric Rheumatology Clinical Studies Group West Midlands Annual Mee.ng Birmingham, 4 th July 03 Professor
More informationCAR T CELL IMMUNOTHERAPY FOR ALL. Stephan Grupp, MD, PhD
CAR T CELL IMMUNOTHERAPY FOR ALL Stephan Grupp, MD, PhD Disclosures Research and/or clinical trial support from Novartis, Servier, Vertex and Kite Study steering committees, consulting, or scientific advisory
More informationTransfusion Medicine Kris0ne Kra1s, M.D.
Transfusion Medicine Kris0ne Kra1s, M.D. Transfusion Medicine Outline Blood groups Introduc0on ABO system Rh system Other systems Blood transfusion Blood products Indica0ons Tes0ng Dangers Transfusion
More informationInflammatory Cell Type? A) Lymphocytes B) Eosinophils C) Neutrophils D) Macrophages E) Mul>nucleated giant cells
Case Study 15 year old young man with mild asthma Admi8ed with 5 day history of cough, myalgias, headache, and subjec>ve fever 3 day history of abdominal pain, nausea, vomi>ng, and fever Developed hypotension,
More informationagvhd standard and experimental therapies
agvhd standard and experimental therapies Anna Maria Raiola Ematologia e Trapianto di midollo Osseo 25 gennaio 2017 IRCCS San Mar3no Genova Impossibile visualizzare l'immagine. La memoria del computer
More informationIntroduction to Pemphigoid: Spectrum of Disease & Treatment
Introduction to Pemphigoid: Spectrum of Disease & Treatment A Razzaque Ahmed, MD Center for Blistering Diseases Boston, MA A.Razzaque.Ahmed@tufts.edu centerforblisteringdiseases.com SPECTRUM OF PEMPHIGOID
More informationFlow cytometry for MRD detec1on: Focus on AML. Sindhu Cherian University of Washington, Sea6le, WA, USA
Flow cytometry for MRD detec1on: Focus on AML Sindhu Cherian University of Washington, Sea6le, WA, USA Residual disease in hematopoie1c malignancy Residual disease has tradi:onal been defined by morphology
More informationWHO position paper on meningococcal vaccines
WHO position paper on meningococcal vaccines Geneva, Switzerland Published in WER Nov 2011 Epidemiology of meningococcal disease In most countries Neisseria meningi+dis is a leading cause of meningi)s
More informationIf a drug trigger is suspected, stop the offending drug as this may reduce the risk of relapse.
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationTransforming patients lives through cellular immunotherapy. Next Generation Cellular Immunotherapy June 2017
Transforming patients lives through cellular immunotherapy Next Generation Cellular Immunotherapy June 2017 1 Overview of Cell Medica Mission: Transform the treatment of cancer with cellular immunotherapy
More informationCAR-T CELLS: NEW HOPE FOR CANCER PATIENTS
CAR-T CELLS: NEW HOPE FOR CANCER PATIENTS Natasha Kekre, MD, MPH, FRCPC Hematologist, Blood and Marrow Transplant Program, TOH Associate Scientist, Ottawa Hospital Research Institute Assistant Professor
More informationPart 2: Cancer Therapies, Present and Future. Adrianna San Roman Leah Liu Clare Malone
Part 2: Cancer Therapies, Present and Future Adrianna San Roman Leah Liu Clare Malone Objec?ves Most cancer therapies aback general features common to all cancers New cancer therapies aback specific features
More informationSarolta Kárpáti. Technology Transfer in Diagnostic Pathology, 5th Central European Regional Meeting May 1, 2010, Siófok
Blistering diseases Sarolta Kárpáti SEMMELWEIS UNIVERSITY, BUDAPEST Technology Transfer in Diagnostic Pathology, 5th Central European Regional Meeting May 1, 2010, Siófok Blistering diseases Autoimmune
More informationMetasta&c prostate cancer. Walid Obeid PGY IV SGHUMC
Metasta&c prostate cancer Walid Obeid PGY IV SGHUMC Defini&on Stage IV prostate cancer : is defined by the American Joint CommiEee on Cancer's TNM classifica&on system: T4, N0, M0, any prostate- specific
More informationAUTOIMMUNE BLISTERING DISEASES; WINDOW TO SYSTEMIC DISEASE
AUTOIMMUNE BLISTERING DISEASES; WINDOW TO SYSTEMIC DISEASE Ron Feldman, MD, PhD Assistant Professor of Dermatology Emory University ron.j.feldman@emory.edu Disclosures I have no conflict of interest to
More informationFor personal use only
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 22 November 2016 The Manager Companies ASX Limited
More informationTransfusion Medicine Kris0ne Kra1s, M.D.
Transfusion Medicine Kris0ne Kra1s, M.D. Transfusion Medicine Outline Blood groups Introduc0on ABO system Rh system Other systems Blood transfusion Blood products Tes0ng Dangers Transfusion Medicine Outline
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationCAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/car-t-cell-therapy-abreakthrough-treatment-for-fighting-cancer/9859/
More informationRituximab in refractory autoimmune bullous diseases
Clinical dermatology Review article doi: 10.1111/j.1365-2230.2006.02151.x Rituximab in refractory autoimmune bullous diseases E. Schmidt, N. Hunzelmann,* D. Zillikens, E.-B. Bröcker and M. Goebeler Departments
More informationRITUXAN (rituximab), NONONCOLOGIC USES
RITUXAN (rituximab), NONONCOLOGIC USES Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical
More informationPsoriasis: Therapeu.c Advances Based on Increased Understanding of Disease Pathways
Psoriasis: Therapeu.c Advances Based on Increased Understanding of Disease Pathways James G. Krueger, MD PhD Professor and Laboratory Head The Rockefeller University Conflicts Research support, consul.ng,
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More informationCancer Immunotherapy: Promises and Challenges. Disclosures
Cancer Immunotherapy: Promises and Challenges David B. Page, MD Medical Oncology PMG East Hematology & Oncology Earle A. Chiles Research Institute Portland, Oregon Disclosures Consulting: Celldex, Nektar,
More informationSYNOPSIS (PROTOCOL WX17796)
TITLE OF THE STUDY A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 52-week trial to assess the efficacy and safety of adjunct MMF to achieve remission with reduced
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationGastrointestinal Toxicities of Checkpoint Blockade
Gastrointestinal Toxicities of Checkpoint Blockade Michael Dougan, MD, PhD Director of the Immunotherapy Mucosal Toxici:es Program Massachuse;s General Hospital 28 June 2018 Disclosures Novar:s Pharmaceu:cs
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More informationImmunotherapies in Cancer: Promise and Burden
Immunotherapies in Cancer: Promise and Burden Rupert Bartsch Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna Faculty Disclosure X
More informationIntravenous Immune Globulin (IVIg)
Policy Number Reimbursement Policy IVIG04272010RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 10/08/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This
More informationGreg Cook Associate Director, Market Access, Bristol-Myers Squibb Australia
NICE PBAC PBS CADTH Access Challenges Greg Cook Associate Director, Market Access, Bristol-Myers Squibb Australia Disclaimer: The views expressed in this presenta5on are those of the author not his employer
More informationPossible cure for hsv 2
Possible cure for hsv 2 Search Herpes Cure Research and News - Safe and Natural Cure for Herpes 1 & Herpes 2. Effective Against HSV 1, HSV 2, Oral and Genital Herpes! For many of those who suffer from
More informationPemphigus Associated with Psoriasis Vulgaris: A Retrospective Study of Seven Patients and a Review of the Literature
2018;26(3):226-232 CLINICAL ARTICLE Pemphigus Associated with Psoriasis Vulgaris: A Retrospective Study of Seven Patients and a Review of the Literature Xian Zhang 1, Xuming Mao 2, Calvina Theresia 1,
More informationPETHEMA; 2 HOVON; 3 PLAG and 4 GATLA Groups.
Clinical significance of complex karyotype at diagnosis in Pa7ents with Acute Promyelocy7c Leukemia Treated with ATRA and chemotherapy based PETHEMA trials Labrador J 1, Montesinos P 1, Bernal T 1, Vellenga
More informationObjectives. Emily Whitehead 10/11/2018. Chimeric Antigen Recepetor T-Cells (CAR-T) CAR-T Therapy: The Past, The Present, and The Future
Objectives CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Review indications for FDA approved CAR-T therapy
More informationPemphigus foliaceus: a clinical study of 32 cases in Hong Kong 32
H.K. Dermatol. Venereol. Bull. (2004) 12, 126-132 Original Article Pemphigus foliaceus: a clinical study of 32 cases in Hong Kong 32 This is a cross-sectional, retrospective study of 32 Hong Kong Chinese
More informationSummer!2016! Undergraduate! Research! Internships!
Summer2016 Undergraduate Research Internships Qualifications:- 1.18yearsofageorolder. 2.MustattendPLU,SeattleU,SPUorbealocalundergraduatemilitaryveteran. 3.EnteringjuniororpreferablysenioryearinFall2016.
More informationBIOTRON LIMITED (ASX:BIT) Broker Meet Biotech August 2018
BIOTRON LIMITED (ASX:BIT) Broker Meet Biotech August 2018 Dr Michelle Miller Managing Director +61 412 313329 mmiller@biotron.com.au www.biotron.com.au Forward Looking Statements This presenta8on may contain
More informationEudraCT number: Page 8 of 42
EudraCT number: 2012-001102-14 Page 8 of 42 5 Trial Synopsis Title Sponsor name North American Sponsor Disease Under Investigation An international, open label, randomised, controlled trial comparing rituximab
More informationA Cure For Wolfram Three Steps 3.0 Fumi Urano, MD, PhD July 16, REPLACE damaged genes &,ssues PROTECT & REGROW remaining,ssues.
A Cure For Wolfram Three Steps 3.0 Fumi Urano, MD, PhD July 16, 2016 REPLACE damaged genes &,ssues PROTECT & REGROW remaining,ssues STOP progression Mechanisms Loss of func,on of WFS1 Calcium Leakage from
More informationCAR-T Therapy: The Past, The Present, and The Future. Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center
CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Objectives Review indications for FDA approved CAR-T therapy
More informationWHO posi)on paper on influenza vaccines*
WHO posi)on paper on influenza vaccines* Geneva, Switzerland Published in the Weekly Epidemiological Record on 23 November 2012 * This posi(on paper is concerned mainly with vaccines and vaccina(on against
More informationImmunity 15/05/12. Overview: Recogni3on and Response INTERCONNECTEDNESS REDUCE REUSE RECYCLE
Overview: Recogni3on and Response Immunity INTERONNETEDNESS REDUE REUSE REYLE s, agents that cause disease, infect a wide range of animals, including humans The immune system recognizes foreign bodies
More informationDeep brain s,mula,on refers to implan,ng electrodes into specific areas of the brain and hooking the electrodes up to pacemaker- like devices in
1 Deep brain s,mula,on refers to implan,ng electrodes into specific areas of the brain and hooking the electrodes up to pacemaker- like devices in order to send signals into the brain to jam the abnormal
More information12th prac*ce: Autoan*body diagnos*cs
12th prac*ce: Autoan*body diagnos*cs Basic Immunology University of Pécs, Clinical Center Department of Immunology and Biotechnology Pécs, 2016. Autoimmunity Autoimmunity: Recogni*on and immune response
More informationDrug Class Prior Authorization Criteria Immune Globulins
Drug Class Prior Authorization Criteria Immune Globulins Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy has been developed through review of
More informationUniversity of Groningen. Acantholysis in pemphigus van der Wier, Gerda
University of Groningen Acantholysis in pemphigus van der Wier, Gerda IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the
More informationEpigene.cs: What is it and how it effects our health? Overview. Dr. Bill Stanford, PhD OFawa Hospital Research Ins.tute University of OFawa
Epigene.cs: What is it and how it effects our health? Dr. Bill Stanford, PhD OFawa Hospital Research Ins.tute University of OFawa Overview Basic Background Epigene.cs in general Epigene.cs in cancer Epigene.cs
More informationAppendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014
Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014 The notification letter which contains details of the decision to widen the restriction criteria for rituximab and eltrombopag
More informationAdvances in Immunotherapy for Lymphoma. Ashley Freeman, MD, FRCPC Immunotherapy Research Fellow
Advances in Immunotherapy for Lymphoma Ashley Freeman, MD, FRCPC Immunotherapy Research Fellow The immune system and cancer Immunotherapies available for lymphoma Upcoming immunotherapy clinical trials
More informationLecture 14 Carbohydrate recogni4on in cell adhesion and signalling
Lecture 14 Carbohydrate recogni4on in cell adhesion and signalling Learning objects The classifica4on of sugar- binding proteins based on structures of carbohydrate- recogni4on domains The roles of mannose-
More informationAdverse effects of IBD therapies: how medica7ons work and what could happen while taking them
Adverse effects of IBD therapies: how medica7ons work and what could happen while taking them Chris7na Ha, MD Center for Inflammatory Bowel Diseases David Geffen School of Medicine at UCLA Treatment Goals
More informationChapter 43 Notes How is a walled city like your immune system?
Chapter 43 Notes How is a walled city like your immune system? St. Malo 1 AP Biology Agenda 1. Warm Up 5 2. Finish Respiration Notes 10 3. Immune System Notes 35 4. Immune System Graphic Organizer 5 5.
More informationherg1 channels: from an2targets to novel therapeu2c targets in oncology
herg1 channels: from an2targets to novel therapeu2c targets in oncology Annarosa Arcangeli 1, Andrea Becche- 2, Olivia Crociani, Massimo D Amico 1, Luca Gasparoli 1, Marika Masselli, Serena Pillozzi 1,
More informationNothing to disclose. Screening for and treatment of Hepa11s B and C 2/18/15
Screening for and treatment of Hepa11s B and C Lisa Winston, MD University of California, San Francisco San Francisco General Hospital Nothing to disclose. 1 Hepa11s B Epidemiology Pathogenesis Lecture
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationACTEMRA (tocilizumab)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Actemra is an agent in the class of drugs known as biologic disease modifiers. It is used to treat adult onset rheumatoid (RA) arthritis, polyarticular
More informationB. Autoimmune blistering diseases
Go Back to the Top To Order, Visit the Purchasing Page for Details formation immediately above the basal layer. The dermal papillae, which are covered by basal cells in the single layer that is left in
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Tisagenlecleucel-T for previously treated B-cell acute lymphoblastic Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
More informationDalazatide, first-in-class Kv1.3 channel blocker, an immunomodulators journey from sea to clinic
Dalazatide, first-in-class Kv1.3 channel blocker, an immunomodulators journey from sea to clinic Aurora Biomed Ion Channels Retreat 2015 Shawn Iadonato Dalazatide: Potential Autoimmune Blockbuster Immune
More informationInspiration for this talk. Introduction to Rituximab. Introduction to Rituximab (RTX) Introduction to Rituximab. Introduction to Rituximab
It was the best of times, it was the worst of times The role of Rituximab in the treatment of Autoimmune Disease Inspiration for this talk Introduction to Rituximab (RTX) Chimeric anti-cd20 mab Approved
More information